Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter.
Phio Pharmaceuticals Stock Down 1.5 %
Shares of PHIO stock opened at $1.29 on Monday. The stock has a market cap of $8.89 million, a P/E ratio of -0.12 and a beta of 1.28. The company’s fifty day simple moving average is $1.71 and its two-hundred day simple moving average is $2.41. Phio Pharmaceuticals has a 52 week low of $1.22 and a 52 week high of $9.79.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What does consumer price index measure?
- MarketBeat Week in Review – 03/24 – 03/28
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
